Fussen Technology Co., Ltd. appears in FDA device records as the applicant for dental computed tomography submissions under product code OAS and regulation number 21 CFR 892.1750, a Class II radiology category. The supplied collection holds one linked 510(k) record, K263033, decided September 30, 2026 with decision code SESE, meaning substantially equivalent. The same collection’s decision counts show one SESE decision, and the single-record sample shows the same one SESE decision; these are counts of the supplied filings as of the snapshot, not measures of company sales, total portfolio or safety performance. The FDA record lists a Shenzhen, Guangdong address for correspondence; that filing address is not evidence of a headquarters location. [1][2][3]
The K263033 clearance and its scope
K263033 covers a Dental Computed Tomography X-ray System with trade names Rubik XSmart, Rubik X1 and Rubik X3, and Matrix 7000 and Matrix 7800 model designations. FDA received the submission August 31, 2026 and issued a substantially equivalent decision on September 30, 2026. The record shows a Special clearance type, no third-party review, a Summary statement and the Radiology advisory committee. The applicant is listed as Fussen Technology Co., Ltd., with Guiqin Zheng identified in a regulatory affairs correspondence role. [1][2]
The FDA database entry for the same submission repeats the device name, product code OAS, regulation number 892.1750 and Class II designation, and records that the submission was not a combination product and had no authorized predetermined change control plan. The page shows a last-updated date of October 19, 2026. [3]
Documented device characteristics
The review correspondence compares the proposed device with predicate K251842, a Dental Computed Tomography X-ray System cleared November 13, 2025 under the same regulation and product code. The comparison table lists identical maximum scan times for the two model families: 30 seconds for Matrix 7000 and 24 seconds for Matrix 7800. It also lists DICOM 3.0 compatibility and a software package named DTKL with patient information management, image acquisition, image viewing, transmission and output functions. [2][4]
Field-of-view options in the predicate document span 16cm by 16cm down to 5cm by 5cm for Matrix 7000 (Rubik X1) and 18cm by 20cm down to 5cm by 5cm for Matrix 7800 (Rubik X3), with active area and pixel size entries of 153.6 by 153.6mm at 100um and 204.8 by 204.8mm at 100um respectively. The K263033 comparison table lists a subset of these fields of view, including 12cm by 10cm, 9cm by 9cm, 8cm by 9cm and 5cm by 5cm, and marks 3D scan mode as similar between the devices. [2][4]
Product lines described by the company
Fussen’s own website lists Cone Beam CT products including D50 CBCT, RUBIK SERIES CBCT and Rubik XSmart, alongside intraoral scanners S6500, S6000 and an intraoral scanner cart, intraoral imaging products such as the F100 intraoral sensor, F200 and F220 image plate systems and the R150 portable X-ray unit, and software named DentalFlex and DentalX. The same page states that the company was established in 2010. These are company-published product listings; the public documents do not establish commercial availability in any market. [6]
A company news post dated November 21, 2025 announced the global launch of the Rubik X Series dental CBCT systems and stated that the series had received European CE certification and U.S. FDA certification. The post is the publisher’s account of its own approvals and launch; the linked FDA records document the K263033 and K251842 clearances specifically. [5]
Applicant identity and what the records do not show
The FDA correspondence for K263033 is addressed to Fussen Technology Co., Ltd. in Shenzhen, Guangdong, and the K251842 letter is addressed to the same legal applicant through a Shanghai-based regulatory representative. The records identify the applicant and its regulatory contacts; they do not identify a parent company, brand owner or corporate group structure. Any relationship between the applicant and the website publisher is not stated in the public documents. [2][4][6]
The public information contains no recall records and no post-market performance data for these devices. The one-record collection and its single SESE decision describe the filings provided as of November 20, 2026, and cannot be read as the company’s complete regulatory history or as evidence about device safety or clinical outcomes. [1][3]

